Bladder cancer · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine and RT Variant #09 | — | R 7 106 | 56d | — | ~15.7 mo | — | — | 2 |
Fluorouracil, Mitomycin, RT Variant #01 | — | R 5 688 | 56d | — | ~18.9 mo | — | — | 1 |
Paclitaxel and RT Variant #01 | — | R 2 428 | — | — | — | — | — | — |
Cisplatin and Fluorouracil (CF) and RT Variant #13 | — | R 1 850 | 28d | ~16.0 mo | ~17.0 mo | ~18 | ~R 33 301 PFS proxy · indirect | 6 |
Cisplatin and RT Variant #01 | — | R 1 500 | 49d | ~16.6 mo | ~58.6 mo | ~11 | ~R 16 502 PFS proxy · indirect | 22 |
Cisplatin and Paclitaxel (TP) and RT N/A - secondary systemic drug | — | R 350 | 28d | — | — | — | — | 1 |
Radiation therapy N/A - radiation Partial | — | — | 49d | — | — | — | — | 3 |
7 of 7 regimens shown